Premium
Delights and let‐downs in the management of tumor necrosis factor receptor‐associated periodic syndrome: the canakinumab experience in a patient with a high‐penetrance T50M TNFRSF 1A variant
Author(s) -
Cantarini Luca,
Lopalco Giuseppe,
Vitale Antonio,
Caso Francesco,
Lapadula Giovanni,
Ian Florenzo,
Galeazzi Mauro,
Rigante Donato
Publication year - 2015
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.12521
Subject(s) - medicine , canakinumab , etanercept , myalgia , hepatosplenomegaly , arthritis , tumor necrosis factor receptor 1 , abdominal pain , anakinra , tumor necrosis factor alpha , immunology , tumor necrosis factor receptor , disease
The anti-IL1 drug canakinumab has been administered in a patient with a high-penetrance T50M TNFRSF1A variant: this experience has been discussed in this manuscript